

ABBVIE LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO PATIENT ORGANISATIONS FOR FINANCIAL YEAR 2025

Name of Patient Organisation	Financial Support Grant	Financial Support Sponsorship	Service Fee	Service Expense	Short Description of Activity (Objective)
Axial Spondyloarthritis International Federation		£38,000.00			Corporate Membership
Blood Cancer Alliance		£15,000.00			Corporate Membership
Blood Cancer UK	£25,000.00				Funding towards support for Transformation Service
Blood Cancer UK			£1,085.00		Funding towards involvement in patient preferences survey
CancerWise	£3,000.00				Funding to support ongoing improvements in patient care
Crohn's & Colitis UK		£15,000.00			Funding to support printing and distribution of patient information materials
CLL Support Association	£15,000.00				Funding towards wellbeing, education and advocacy programme
Eczema Outreach Support	£10,000.00				Funding to support ongoing improvements in patient care
Every Youth	£5,000.00				Funding to support Every Youth Healthy project
Harry's Hydrocephalus Awareness Trust	£5,000.00				Funding to support Get-A-Head project
Health Equality and Rights Organisation (t/a LGBT HERO)	£500.00				Funding to support Stronger Together project
Hep C Trust	£20,000.00				Funding to support ongoing improvements in patient care

IBDrelief		£712.00		Consultancy services to support development of Disease Awareness Campaign
IBDrelief		£620.00	£33.40	Participation in steering committee
International Agency for the Prevention of Blindness (IAPB)		£115,000.00		Corporate Membership
International Agency for the Prevention of Blindness (IAPB)		£27,500.00		Sponsorship of IAPB Policy Roundtable activities
International Agency for the Prevention of Blindness (IAPB)		£27,500.00		Sponsorship of Diabetic Eye Coalition
International Agency for the Prevention of Blindness (IAPB)			£5,665.00	Funding towards creation of advocacy toolkit
Leukaemia Care		£10,000.00		Funding to support ongoing improvements in patient care
Lyme Resource Centre		£1,250.00		Funding to support prevention of Lyme Disease's associated health risks
Lymphoma Action		£15,000.00		Funding towards information services and patient materials
National Axial Spondyloarthritis Society		£15,000.00		Funding towards 'Aspiring to Excellence' programme
The Neurological Alliance			£12,948.00	Corporate Membership
Ovacome		£10,000.00		Funding towards the 'staying connected' programme
Ovacome		£465.00		Consultancy services to advise on patient journey
Ovacome		£285.00	£76.50	Participation in AbbVie internal meeting
Ovacome		£620.00		Delivery of disease awareness training session
Ovarian Cancer Action		£10,000.00		Funding to support Ovarian Cancer Symptoms Checker Tool
Parkinsons UK		£310.00		Consultancy services to support development of Disease Awareness videos
Parkinsons UK		£4,000.00		Sponsorship of Par Con conference
Parkinsons UK		£310.00		Consultancy services to support development of Disease Awareness videos

Patients Association	£15,000.00			Funding to support ongoing improvements in patient care
Peaches Womb Cancer Trust	£3,000.00			Funding to support Peaches Packs development
Target Ovarian Cancer	£10,000.00			Funding towards online digital event
The Migraine Trust	£29,969.00			Funding to support ongoing improvements in patient care
The Migraine Trust		£193.75	£99.75	Participation in AbbVie-organised parliamentary event
Usher Kids UK	£4,100.00			Funding to support Annual Family Information Day

ABBVIE LTD TRANSPARENCY DISCLOSURE METHODOLOGICAL NOTES FOR REPORTING YEAR 2025

As a member company of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Association of the British Pharmaceutical Industry (ABPI), **AbbVie Ltd** is committed to ensuring that the nature and scope of partnerships and transfers of value (ToV) to Patient Organisations are clear and transparent to the public. Therefore, AbbVie Ltd has published applicable ToV provided directly or indirectly to Patient Organisations for the 2025 calendar year.

This Methodological Note provides guidance on how AbbVie Ltd has recorded and publicly reported this information in accordance with the current edition of the ABPI Code of Practice.

Reporting period/Reportable ToV:

The AbbVie Ltd 2025 disclosure includes applicable ToV during the period between 1st January and 31st December 2025. The applicable ToV relate to payments made within the disclosure period. Payments made from 1st January 2026 will be considered for the next report.

Defining Reportable Organisations:

The ABPI definition of Patient Organisations is broad, so additional factors were taken into consideration when determining whether ToV to organisations were reportable under the category of Patient Organisation.

These included but were not limited to the following in relation to a health condition or disability: provision of information and support services, hosting of campaigns and events to raise awareness, involvement in policy activities to improve patient outcomes, community engagement and provision of other support related to patients' healthcare, except where activities were delivered based on AbbVie's confidential contractual obligations in relation to third parties that are not Patient Organisations (e.g., the NHS).

Transparency Acknowledgment from Patient Organisations:

Agreements between AbbVie Ltd and Patient Organisations relating to ToV have a Transparency section which includes notification of AbbVie's Transparency disclosure obligations.

Validation Approach:

AbbVie has conducted a validation exercise with Patient Organisations contained within this reporting period to make them aware of the disclosure and provide an opportunity to verify any ToV.

Cross Border Interactions:

These ToV include engagements between AbbVie Global/Europe and UK Patient Organisations where these have occurred. For example, where a Patient Organisation has participated in an AbbVie Global/European programme or activity.

National Contracts and Tenders:

AbbVie does not disclose transfers of value related to national contracts or tenders. These arrangements are awarded through competitive procurement processes and maintaining confidentiality is essential to ensuring a fair competitive market while maintaining our compliance obligations.

ToV Definitions:

Each ToV includes a category label and brief description of the activity it relates to. The category and associated descriptors are as follows:

Financial Support, including Grants, Sponsorships and Services:

- Grants:
 - » Definition: Funding provided by AbbVie, in whole or in part, for activities carried out by a Patient Organisation, for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the patient organisation to provide goods or services in return.
 - » Examples: unrestricted grants for the development of patient materials
- Sponsorship:
 - » Definition: Financial or non-financial support provided in whole or in part, by AbbVie for activities carried out by a Patient Organisation for the purpose of supporting healthcare, scientific research or education. Sponsorships are provided at an arm's length arrangement without AbbVie's involvement in the activities or the development of any associated content event/meetings or other materials. AbbVie may receive benefits as agreed with the patient organisation e.g. invitations to appropriate events and access to project / activity results and insights.
 - » Examples: Sponsorship of educational material, sponsorship of webinars/events.
- Services:
 - » Definition: Services provided by the Patient Organisation to AbbVie, including fees and appropriate expenses in relation to the services delivered
 - » Examples: Participation in or speaking at an AbbVie meeting or Advisory Board, review of AbbVie materials for patients.

Fees and expenses have been disclosed separately. This includes expenses such as transport or accommodation costs incurred to take part in the associated activity, including those activities that were reimbursed or paid directly by AbbVie.

All services are remunerated at Fair Market Value.

Value Added Tax (VAT):

Where applicable, disclosure of payments does not include VAT.

Currency:

All information is reported in Pound Sterling (GBP).

Exchange Rate:

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Ltd Treasury Monthly Average Rates.

Multi-year Contracts:

Activities with ToV crossing calendar years may have the contracted full amount disclosed using the date of last payment.

Post Publication Disputes:

AbbVie will review and investigate disputes with Patient Organisations relative to our disclosures. Any changes resulting from this review will be published in an updated report.